Skip to main content

Table 1 Comparison of the distributions of patient characteristics in the radiochemotherapy groups (30–40 mg/m2 of cisplatin weekly vs. 100 mg/m2 of cisplatin on days 1, 22 and 43; Chi-square test)

From: Comparison of weekly administration of cisplatin versus three courses of cisplatin 100 mg/m2 for definitive radiochemotherapy of locally advanced head-and-neck cancers

  Cisplatin weekly N patients (%) Cisplatin 100 mg/m2 N patients (%) P
Age
 ≤56 years (N = 67) 37 (49) 30 (52)  
 ≥ 57 years (N = 66) 38 (51) 28 (48) 0.92
Gender
 Female (N = 29) 15 (20) 14 (24)  
 Male (N = 104) 60 (80) 44 (76) 0.86
ECOG Performance score
 0–1 (N = 115) 64 (85) 51 (88)  
 2 (N = 18) 11 (15) 7 (12) 0.92
Primary tumor site
 Oropharynx (N = 69) 36 (48) 33 (57)  
 Hypopharynx (N = 19) 12 (16) 7 (12)  
 Larynx (N = 30) 19 (25) 11 (19)  
 Oral cavity/Floor of mouth (N = 15) 8 (11) 7 (12) 0.88
T-category
 T1-2 (N = 16) 9 (12) 7 (12)  
 T3-4 (N = 117) 66 (88) 51 (88) 0.99
N-category
 N0-2a (N = 66) 39 (52) 27 (47)  
 N2b-3 (N = 67) 36 (48) 31 (53) 0.75
Histologic grading
 G 1–2 (N = 85) 49 (65) 36 (62)  
 G3 (N = 48) 26 (35) 22 (38) 0.89
Cumulative cisplatin dose
 ≤200 mg/m2 (N = 85) 51 (68) 34 (59)  
 >200 mg/m2 (N = 48) 24 (32) 24 (41) 0.50
  1. After Bonferroni correction for multiple tests (8 tests), p-values of <0.006 were considered significant